ストックスクリーナーアプリを入手
8.38
4.62%
0.37
プレマーケット:
8.37
-0.01
-0.12%
前日終値:
$8.01
開ける：
$7.77
24時間の取引高:
215.11K
Relative Volume:
0.26
時価総額：
$309.22M
収益：
-
当期純損益:
-
株価収益率:
-3.3258
EPS:
-2.5197
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-13.70%
1か月 パフォーマンス:
-16.87%
6か月 パフォーマンス:
+376.14%
1年 パフォーマンス:
+280.91%
1日の値動き範囲:
$7.3129
$8.38
1週間の範囲:
$7.21
$9.98
52週間の値動き範囲:
$0.8786
$12.09
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Compare ANL vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
8.38 | 295.57M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-13 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-06-02 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-09-04 | 開始されました | H.C. Wainwright | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr (ANL) 最新ニュース
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Ionis Pharmaceuticals (IONS) and Axsome Therapeutics (AXSM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Palvella Therapeutics (PVLA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Integer Holdings (ITGR) and Tonix Pharma (TNXP) - The Globe and Mail
Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Should I buy Adlai Nortye Ltd. Sponsored ADR (ANL) - Zacks Investment Research
Adlai Nortye upgraded to Buy at H.C. Wainwright as AN9025 enters clinic - TipRanks
H.C. Wainwright upgrades Adlai Nortye stock rating to Buy with $16 target - Investing.com South Africa
Adlai Nortye Doses First Patient in Global Phase 1 Trial of Pan-RAS Inhibitor AN9025 - TipRanks
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations - GlobeNewswire Inc.
Short Interest in Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Rises By 458.7% - MarketBeat
Adlai Nortye Secures $140 Million PIPE Financing to Support Oncology Pipeline - The Globe and Mail
Adlai Nortye raises $140 million in private placement By Investing.com - Investing.com South Africa
Adlai Nortye prices 64.6M shares at $2.17 in private placement - TipRanks
Adlai Nortye raises $140 million in private placement - Investing.com
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Large Decrease in Short Interest - Defense World
AIFU Inc. – Sponsored ADR (NASDAQ:AIFU) Short Interest Update - Defense World
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.11% By Investing.com - Investing.com India
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.11% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.11% - Investing.com
Lucid Capital Markets initiates coverage on Adlai Nortye stock with Buy rating - Investing.com India
Lucid Capital Markets initiates coverage on Adlai Nortye stock with Buy rating By Investing.com - Investing.com South Africa
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update - MarketBeat
What's going on in today's after hours session - ChartMill
Analysts’ Top Healthcare Picks: Kura Oncology (KURA), UnitedHealth (UNH) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Aprea Therapeutics (APRE), Arcellx Inc (ACLX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Significant Increase in Short Interest - Defense World
Short Interest in Global X Social Media ETF (NASDAQ:SOCL) Increases By 7,184.3% - Defense World
TerraVest Industries (TSE:TVK) Price Target Raised to C$209.00 at Canaccord Genuity Group - Defense World
Paycom Software (NYSE:PAYC) Price Target Cut to $185.00 by Analysts at Barclays - Defense World
Teledyne Technologies (NYSE:TDY) Given New $579.00 Price Target at Barclays - Defense World
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Up 6,821.4% in December - MarketBeat
Adlai Nortye narrows first-half 2025 loss as oncology pipeline advances - MSN
Why Baidu Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - Sahm
Adlai Nortye Ltd. Shareholders Approve Redomiciliation to Singapore - MSN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Xoma (XOMA) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - Sahm
Adlai Nortye Narrows First-Half 2025 Loss as Oncology Pipeline Advances - The Globe and Mail
Adlai Nortye Ltd ADR (ANL-Q) Stock Price and News - The Globe and Mail
Adlai Nortye licenses cancer drug to ASK Pharm in $230 million deal By Investing.com - Investing.com South Africa
Adlai Nortye shares soar on $230 million licensing deal with ASK Pharm By Investing.com - Investing.com South Africa
Adlai Nortye shares soar on $230 million licensing deal with ASK Pharm - Investing.com India
Adlai Nortye Licenses Pan-RAS Inhibitor AN9025 to ASK Pharm for Greater China - TipRanks
Adlai Nortye licenses cancer drug to ASK Pharm in $230 million deal - Investing.com
Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China - Sahm
Adlai Nortye (NASDAQ:ANL) Trading 1% HigherWhat's Next? - MarketBeat
Adlai Nortye (NASDAQ:ANL) Trading 1% Higher – What’s Next? - Defense World
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Regeneron (REGN) - The Globe and Mail
Adlai Nortye Ltd. Sponsored ADR Cash Flow – LS:A3EEED - TradingView — Track All Markets
Total common shares outstanding of Adlai Nortye Ltd. Sponsored ADR – LS:A3EEED - TradingView — Track All Markets
Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Terns Pharmaceuticals (TERN) and Pyxis Oncology (PYXS) - The Globe and Mail
Adlai Nortye Ltd Adr (ANL) 財務データ
Adlai Nortye Ltd Adr (ANL) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):